

Supplementary appendix

Table S1. Literature search strategy

Database(s): **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions(R)** Search Strategy: 1st of January 1984 to July 30th 2021

#	Searches
1	chronic disease/ or multiple chronic conditions/ or non communicable disease/
2	(chronic disease* or chronic disorder* or chronic* sick* or chronic health condition* or chronic medical condition* or chronic* ill* or long term condition* or multimorbidit* or mult imorbidit*).mp.
3	(non-communicable disease* or non-infectious disease* or noncommunicable disease* or noninfectious disease*).mp.
4	(cardiovascular disease* or coronary artery disease* or myocardial isch?emia or myocardial infarct* or pulmonary disease* or chronic obstructive pulmonary or chronic obstructive lung or chronic obstructive respiratory or diabetes or coronary heart disease* or neoplasm* or cancer*).mp.
5	(hypertension or hypertriglycerid?emi* or hyper triglycerid?emi* or high triglyceride* or high cholesterol or hypercholesterol?emi* or hyperlipid?emia* or hyperlipidemi*).mp.
6	(diastolic pressure or systolic pressure or blood pressure or cardiometabolic syndrome*).mp.
7	(copd or asthma or renal disease* or kidney disease*).mp.
8	1 or 2 or 3 or 4 or 5 or 6 or 7
9	Primary Health Care/
10	Delivery of Health Care/
11	(primary health system or primary health service or primary healthcare system or primary health care system or primary healthcare service or primary health care service or primary medical service delivery or primary medical care service or primary care service or primary care system).mp.
12	(first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*).mp.
13	((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*).mp.
14	9 or 10 or 11 or 12
15	8 and 14
16	(readiness or preparedness or capacity or quality improvement or quality of Improvement).mp.
17	15 and 16
18	((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) adj5 (accessibility or availability)).mp.
19	8 and 18
20	((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) adj (need* or demand*).mp.
21	8 and 20
22	((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*) adj3 (need* or demand*).mp.

23	8 and 22
24	17 or 19 or 21 or 23
25	limit 24 to english language
26	limit 25 to (case reports or comment or editorial or letter or news)
27	25 not 26

Database(s): Embase Classic+Embase**Search Strategy:**

#	Searches
1	exp antineoplastic agent/ or cancer therapy/ or bone marrow purging/ or bone marrow rescue/ or exp cancer adjuvant therapy/ or exp cancer chemotherapy/ or cancer gene therapy/ or cancer hormone therapy/ or exp cancer immunotherapy/ or exp cancer radiotherapy/ or multimodality cancer therapy/ or oncolytic virotherapy/ or target cell destruction/ or immunotherapy/ or adoptive immunotherapy/ or exp chimeric antigen receptor immunotherapy/ or radioimmunotherapy/ or exp radiotherapy/ or exp bone marrow transplantation/ or exp hematopoietic stem cell transplantation/ or stem cell transplantation/ or cancer patient/ or cancer survivor/
2	exp neoplasm/dt, rt [Drug Therapy, Radiotherapy]
3	(anti-cancer* or anti-neoplas* or anticancer* or antineoplas* or anticancerogen* or anticarcinogen* or anti-carcinogen* or anti-tumo?r* or antitumor?r* or cancer inhibitor* or tumo?r inhibitor* or anti-leukemi* or antileukemi* or oncotherap* or antimetastatic* or anti-metastatic* or antimetastas#s or anti-metastas#s).mp.
4	((cancer* or tumo?r* or neoplas* or carcinoma* or malignan* or adenocarcinoma* or sarcoma* or lymphoma* or leukemi* or blastoma* or carcinostatic or oncolog* or carcinocidal or oncocidal or oncostatic) adj3 (therap* or drug* or agent* or chemotherap* or electrochemotherap* or treat* or medication* or compound* or immunotherap* or immunological or immunomodul* or immunomodurat*).mp.
5	((adenoma* or chondrosarcoma* or osteosarcoma* or rhabdomyosarcoma* or astrocytoma* or ependymoma* or glioma* or neuroblastoma* or medulloblastoma* or oligodendroglioma* or pheochromocytoma* or retinoblastoma* or cholangiocarcinoma* or melanoma* or mesothelioma* or pheochromocytoma* or paraganglioma* or craniopharyngioma* or esthesioneuroblastoma* or myeloma*) adj (therap* or treatment* or drug* or agent* or medication* or vaccine*).mp.
6	((cancer or tumo?r) adj (cure* or healing or remed* or vaccin* or adjuvant therap* or multichemotherap* or polychemotherap* or gene therap* or hormon* therap* or radiation or irradiation or ablation or immun* therap*).mp.
7	((cancer or carcinoma or adenocarcinoma or sarcoma or lymphoma or leukemia or blastoma or adenoma or chondrosarcoma or osteosarcoma or rhabdomyosarcoma or astrocytoma or ependymoma or glioma or neuroblastoma or medulloblastoma or oligodendroglioma or pheochromocytoma or retinoblastoma or cholangiocarcinoma or melanoma* or mesothelioma or pheochromocytoma or paraganglioma or craniopharyngioma or esthesioneuroblastoma or myeloma or oncolog*) adj (patient* or survivor* or sufferer*).mp.
8	(alkylating adj (agent* or chemical* or compound* or cytostatic*).mp.
9	((((angiogenesis or neovascularisation or tumo?r vascularisation) adj inhibitor*) or ((angiostatic or anti-angiogenesis or antiangiogenesis or anti-angiogenic or antiangiogenic or antimutagenic) adj (agent* or drug*))).mp.
10	(abecomotide or abemaciclib or abexinostat or abieslactone or abivertinib or abrotanone or aburatubolactam A or aburatubolactam C or abyssinone V or acalabrutinib or acalisib or aceglatone or acodazole or adaphostin or adarotene or adavosertib or aderbasib or afamitresgene autoleucel or afatinib or afuresertib or Agaricus blazei extract or agatolimod or agerafenib or aglatimagene or besadenovec or albicanyl acetate or aldesleukin or alectinib or alicdamotide or alisertib or adozelesin or alkanesulfonic acid or amsacrine or amsacrine derivative or asulacrine isethionate or busulfan or dimethylbusulfan or mesylic acid or mesylic acid derivative or mesylic acid ethyl ester or mesylic acid methyl ester or mesylmesylic acid 2 chloroethyl ester or methylene dimesylate or treosulfan or ametantrone or anaxirone or aziridine derivative or apaziquone or azimexon or aziridine or aziridinybenzoquinone or azirine derivative or carboquone or ciamexon or diaziquone or dipin or pumitepa or

	<p>thiotepa or tretamine or tretazicar or triaziquone or uredepa or banoxantrone or bisantrene or bizelesin or brostallicin or carboplatin or carzelesin or chlormethine derivative or acridine mustard or aldophosphamide or alestramustine or ambamustine or amustaline or aniline mustard or bendamustine or benzoquinone mustard or bestrabucil or canfosfamide or chlorambucil or chlormethine or chlornaphazine or cloturin or cortifen or cyclophosphamide or cydrin or dichlorodiethylamine or dopan or estramustine or evofosfamide or galamustine or glufosfamide or gonadorelin or ifosfamide or laromustine or mafosfamide or mafosfamide cyclohexylamine or mafosfamide lysine or mannomustine or melphalan or mepacrine mustard or palifosfamide or peptichemio or perfosfamide or phenesterin or phosphoramidate mustard or sarcolysin or sufosfamide or tallimustine or tinostamustine or trofosfamide or uramustine or xylamine or cisplatin or cyclodisone or dacarbazine or dianhydrogalactitol or etoglucid or imidacrine or irofulven or ledoxantrone or losoxantrone or mitoxantrone or nitrosourea derivative or bofumustine or butylnitrosourea or carmustine or chloroethylnitrosourea or chloroethylnitrosourea derivative or cystemustine or ecomustine or elmustine or estradiol 17 or ethylnitrosourea or fotemustine or lomustine or methylnitrosourea or nimustine or nitrosourea or prednimustine or ranimustine or semustine or spirazidine or spiromustine or streptozocin or tauromustine or nortopixantrone or oxanthazole or pentamethylmelamine or pixantrone or procarbazine or teloxantrone or temozolomide or topixantrone or alobresib or alpelisib or alpha sarcin or altemicidin or alteminostat or altiratinib or altretamine or ambazone or amcasertib or amidox or aminothiadiazole or amonafide or amphethinile or amphidinolide A or amphidinolide B or amphidinolide D or amsilarotene or amuvatinib).mp.</p>
11	<p>(acrizanib or aflibercept or aganirsen or alofanib or anecortave or anginex or angiostatic protein or angiostatin or angiozyme or atiprimod or avadomide or axitinib or beloranib or bermekimab or bevasiranib or brivanib or cabozantinib or canstatin or caplostatin or carlumab or carotuximab or cediranib or cenupatide or cetuximab or cilengitide or combretastatin A1 phosphate or conbercept or conendostatin or crenolanib or crizotinib or dalantercept or depudecin or dovitinib or endostatin or endothelial monocyte activating polypeptide II or fexapotide or foretinib or foslinanib or fruquintinib or fumagillol chloroacetylcarbamate or glesatinib or infigratinib or lapatinib plus pazopanib or lenalidomide or lenvatinib or linifanib or lucitanib or maspin or monoclonal antibody DC101 or monoclonal antibody imc 1c11 or motesanib or muparfostat or dicarboxamide or navicixizumab ornintedanib or ofranergene obadenovec or oglufanide or orantinib or paclitaxel or pazopanib or pegaptanib or pegdinetanib or pegpleranib or pixatimod or pomalidomide or ranibizumab or recombinant endostatin or regorafenib or relzomostat or rinucumab or risuteganib or ronaparstat or semaxanib or "siRNA 027" or sonopizumab or sorafenib or squalamine or sunitinib or tanomastat or tasquinimod or tesevatinib or thalidomide or thrombospondin 1 or thrombospondin 2 or tigapotide or tiomolibdate choline or tirbanibulin or tivozanib or toceranib or trabedersen or trebananib or tumstatin or vandetanib or varisacumab or vascular endothelial growth inhibitor or vascular endothelial cell growth inhibitor or vascular endothelial growth factor antagonist vascular endothelial growth factor inhibitor or VEGF inhibitor or vasculotropin inhibitor or abicipar pegol or bevacizumab or brotuzumab or catequentinib or dilpacimab or faricimab or olinvacimab or pamufetinib or ramucirumab or rivoceranib or sintilimab or vulinacimab vatalanib or volociximab or vorolanib or metastasis inhibitor or carcinostatic alkaloid or acronine or afeletecan or atiratecan or becatecarin or belotecan or camptothecin or topotecan or cephalotaxine or coralyne or cositecan or cyclopamine or datelliptium chloride or deacetylvinblastine or demecolcine or diazepinomicin or diflomotecan or ellipravin or ellipticine or elliptinium or elomotecan or etirinotecan pegol or etoposide or exatecan or exatecan alideximer or fagaronine or firtecan or gimatecan or govitecan).mp.</p>
12	<p>(harringtonine or homoharringtonine or indicine n oxide or indirubin or irinotecan or lorvotuzumab mertansine or lurbinectedin or maytansine or mitopodozide or mureletecan or namitecan or napavin or narciclasine or nitidine or olivacine or patidegib or pazelliptine or pegamotecan or retelliptine or rubitecan or senecionine or sinococuline or solamargine or swainsonine or tenifatecan or teniposide or thalicarpine or trabectedin or trewiasine or trimethylcolchicine acid or vinblastine or vincristine or vindesine or vinflunine or vinfosiltine or vinleucinol or vinleurosine or vinorelbine tartrate or vintafolide or vintriptol or vinzolidine or withanolide or carcinostatic antibiotic or 21 aminoepithilone B or 3 deazaaristeromycin or actinobolin or 7 aminodactinomycin or actinomycin derivative or adozelesin or alanosine or alvespimycin or ankinomycin or anthracycline antibiotic agent* or 11 deoxydaunorubicin or 2 fluoroidarubicin or 2 pyrrolinodoxorubicin or 4 demethoxy 11 deoxydaunomycinone or 4 demethoxydaunomycinone or 4 demethoxydoxorubicin or 4 iodoesorubicin or 5 iminodaunorubicin or 9 deacetyl 9 methylidarubicin or 9 deoxydoxorubicin or aclacinomycin or aclacinomycin B or aclarubicin or adriamycinone or aklavinone or aldorubicin or amrubicin or annamycin or anthracycline or anthracyclinone derivative or barminomycin I or berubicin or camsirubicin or carubicin or cinerubin A or</p>

	<p>cinerubin B or daunomycinone or daunorubicin or monoclonal antibody conjugate or daunorubicinol or decilrubicin or detorubicin or ditrisarubicin B or doxorubicin or doxorubicinol or epirubicin or epirubicinol or epsilon rhodomycinone or esorubicin or galarubicin or gancotamab or idarubicin or idarubicinol or ladirubicin or leurubicin or n benzyldoxorubicin 14 valerate or n trifluoroacetyldoxorubicin or n trifluoroacetyldoxorubicin 14 hydrogen adipate or nemorubicin or obelmycin or oxaunomycin or pirarubicin or pyrromycinone or rhodomycin A or rodorubicin or ruboxyl or sabarubicin or valrubicin or viriplanin A or zoptarelin doxorubicin or zorubicin or anthramycin or arasangivamycin or asperlin or auromomycin or azaserine or bactobolin or bizelesin or blasticidin S or bleomycin or bleomycinic acid or liblomycin or pepleomycin or cactinomycin or cadeguomycin or calicheamicin or gemtuzumab or inotuzumab ozogamicin or calphostin or caplostatin or carzelesin or chartreusin or chlorozotocin or chromomycin or chrysomycin or colabomycin A or congocidine or cordycepin or dactinomycin or dehydroididemnin B or dehydroxysparsomycin or didemnin or distamycin A derivative or duocarmycin or duocarmazine or duocarmycin SA or dynemicin A or echinomycin or echinosporin or elsamicin A or epothilone or esperamicin or formycin or fostriecin or fredericamycin A or fumagillin or fumagillol).mp.</p>
13	<p>(geldanamycin or gilvocarcin V or glidobactin or granaticin or hadacidin or herbimycin or himastatin or illudin or irofulven or ixabepilone or kapurimycin or kedarcidin or leinamycin or lidamycin or luzopeptin or mabecin I or macromomycin or marcellomycin or menogaril or mithramycin or 7 n acetylmitomycin C or mitomycin or porfiromycin or musettamycin or mycophenolic acid or n bromoacetyldistamycin A or neothramycin or neplanocin A or nogalamycin or olivomycin or oxanosine or ozogamicin or pactamycin or pibenzimol or pibrozelesin or pirazofurin or prodigiosin or puromycin or pyrindamycin A or pyrindamycin B or quinocarcin or rachelmycin or rebeccamycin or resorthiomycin or retaspimycin or reumycin or rodaplutin or romidepsin or rubomycin or rufocromomycin or saframycin or sagopilone or sangivamycin or sapurimycin or sarkomycin or showdomycin or sibiromycin or sparsomycin or spergualin orspicamycin or spongistatin 1 or spongistatin 2 or streptonigrin derivative or tallysomycin or tanespimycin or tetracenomycin C or thiocoraline or thrazarine or tomaymycin or tubercidin or tuftsin or vicenistatin or yunnanmycin or zinostatin or buthionine sulfoximine or folic acid antagonist or folic acid antimetabolite or pteroylglutamic acid antimetabolite or 10 deazaaminopterin or 7 hydroxymethotrexate or aminopterin or arfolitixorin or bromebric acid or dichloromethotrexate or edatrexate or gamma fluoromethotrexate or homofolic acid or lometrexol or metesind or methotrexate or metodiclufen or nolatrexed or pelitrexed or pemetrexed or piritrexim or plevitrexed or pralatrexate or raltitrexed or talotrexin or triazinate or trimetrexate or oxythiamine or purine antagonist or 4 carbamoylimidazolium 5 olate or 6 methylthioinosine or 6 n benzyladenosine or 8 azaguanine or azaguanosine or azathioprine or cladribine or clofarabine or cloturin or deoxythioguanosine or dezaguanine or fludarabine or guanine 7 oxide or guanine arabinoside or mercaptopurine or nelarabine or pentostatin or selenazofurin or sulfenosine or sulfinosine or sulfonosine or thioguanosine or tiazofurin or tioguanine or pyrimidine antagonist or 3 dezaauridine or 3 ethynylcytidine or 5 chlorodeoxycytidine or 5 hydroxymethyldeoxyuridine or 5 aminothymidine or 5 deoxy 5 fluorocytidine or 6 azacytidine or ancitabine or azacitidine or azaauracil or azaauridine or brequinar or bromodeoxycytidine or capecitabine or carmofur or cloxuridine or cytarabine or cytarazid or decitabine or dihydrofluorouracil or doxifluridine or elacytarabine or emitetur or enocitabine orfazarabine or fiacitabine or floxuridine or flucytosine deoxyriboside or fluorouracil or fluorouridine or fosfluridine tidoxil or fosgemcitabine palabenamide or fosifloxuridine nafalbenamide or galocitabine or gemcitabine or gimeracil plus oteracil potassium plus tegafur or guadecitabine or orzel or ropidoxuridine or sapacitabine or tegafur or tezacitabine or tipiracil plus trifluridine or troxacitabine or uracil arabinoside).mp.</p>
14	<p>(4 hydroxytoremifene or abiraterone or acetylsalicylic acid plus aluminum hydroxide plus ascorbic acid plus prednisone or acetylsalicylic acid plus caffeine plus phenacetin plus prednisolone or acetylsalicylic acid plus calcium carbonate plus methylprednisolone or acetylsalicylic acid plus calcium carbonate plus prednisolone or acetylsalicylic acid plus methylprednisolone or acetylsalicylic acid plus prednisolone or acolbifene or afimoxifene or aluminum hydroxide plus ascorbic acid plus prednisone plus salicylamide or aluminum hydroxide plus calcium ascorbate plus calcium carbonate plus pantothenate calcium plus potassium salicylate plus prednisone or aluminum hydroxide plus magnesium trisilicate plus pantothenate calcium plus prednisolone or aluminum hydroxide plus magnesium trisilicate plus prednisone or amcenestran or angiopeptin or apalutamide or aromatase inhibitor or estrogen synthetase inhibitor or oestrogen synthetase inhibitor or steroid aromatase inhibitor or abyssinone II or aminoglutethimide or anastrozole or atamestane or exemestane or fadrozole or finrozole or formestane or leflutrozole or letrozole or liarozole or minamestane or plomestane or pyridoglutethimide or testolactone or vorozole or arzoxifene or ascorbic acid plus chlorpheniramine maleate plus prednisone or ascorbic acid plus chlorpheniramine plus prednisone or avorelin or bestrabucil or bicalutamide or buserelin or calcium</p>

	<p>phosphate dibasic plus cyanocobalamin plus ethinylestradiol plus methylphenidate plus methyltestosterone plus nicotinamide plus pyridoxine plus riboflavin plus thiamine or calusterone or carisoprodol plus prednisolone or chloramphenicol plus prednisolone or chlorbutol plus phenylephrine plus prednisolone acetate or chlorotrianisene or chlorpheniramine gluconate plus prednisolone acetate or chlorzoxazone plus paracetamol plus prednisolone or conjugated estrogen or cyproterone or deslorelin or diethylstilbestrol derivative or dienestrol or diethylstilbestrol or fosfestrol or hexestrol or methestrol or dimethylstilbestrol or droloxifene or drostanolone or ectylurea plus ethoxzalamide plus medroxyprogesterone acetate or endoxifen or enzalutamide or ephedrine plus phenobarbital plus prednisone plus theophylline or estradiol undecylate or ethinylestradiol or fluoxymesterone or flutamide or fulvestrant or galeterone or gentamicin plus prednisolone acetate or gestonorone or goserelin or gramicidin plus neomycin plus phenylephrine plus prednisolone acetate or hydroxyflutamide or hydroxyprogesterone or hydroxytamoxifen or hydroxyzine plus prednisolone or idoxifene or leuprorelin or medroxyprogesterone or megestrol or melengestrol or mephenesin plus methylphenobarbital plus prednisone or mepitiostane).mp.</p>
15	<p>(methoxyphenamine plus methylprednisolone or methylprednisolone or methyltestosterone or miproxifene or nafarelin or nandrolone or neomycin plus phenylephrine plus phenylpropanolamine plus prednisolone sodium phosphate or neomycin plus phenylephrine plus prednisolone or neomycin plus phenylephrine plus prednisolone acetate or neomycin plus polymyxin B plus prednisolone acetate or neomycin plus prednisolone or neomycin plus prednisolone acetate or neomycin plus prednisolone sodium phosphate or nilutamide or nortamoxifen or ormeloxifene or orteronel or ospemifene or ozarelix or panomifene or phenylephrine plus prednisolone or pipendoxifene or polyestradiol or prednisolone or prednisone or raloxifene or seviteronel or sivifene or tamoxifen or tesmilifene or testololactone or testosterone propionate or toremifene or trioxifene or triptorelin or zanoterone or zindoxifene or zoptarelin doxorubicin or antineoplastic metal complex or amminebisbutyratodichloro cyclohexylamine platinum or bleomycin cobalt or bleomycin copper or budotitane or capecitabine plus oxaliplatin or carboplatin or carboxyethylgermanium sesquioxide or cisplatin or clivatuzumab tetraxetan or cycloplatin or doxorubicin copper or doxorubicin iron or enloplatin or epratuzumab tetraxetan yttrium y 90 or eptaplatin or imifoplatin or iproplatin or labetuzumab tetraxetan yttrium y 90 or lilotomab satetraxetan lutetium lu 177 or lintuzumab satetraxetan actinium ac 225 or lobaplatin or malopen or miboplatin or miriplatin or nedaplatin or oxaliplatin or oxoplatin or pasireotide tetraxetan gallium ga 68 or picoplatin or platinum ammine cyclohexylamine dichloride or platinum ethylenediamine dichloride or satoreotide tetraxetan or satraplatin or sebriplatin or spirogermanium or spiroplatin or tacatuzumab tetraxetan yttrium y 90 or tetrachloroplatinate potassium or tetrachloroplatinum fast black or tetraplatin or tetulomab tetraxetan lutetium lu 177 or titanocene or triplatin tetranitrate or vipivotide tetraxetan or zeniplatin or antroquinonol or apicidin or apitolisib or aplysianin E or apoptin or apoptosis inducing factor or 2 hydroxymethyl 2 methoxymethyl 3 quinuclidinone or arsenic trioxide or clezutoclast or daratumumab or genistein or isotretinoin or lisavanbulin or moxetumomab pasudotox or otenaproxesul or rimiducid or tapotoclast or apricoxib or arenastatin A or asciminib or aspacytarabine or asparaginase or asunercept or atuvaciclib or audencel or avanbulin or avapritinib or avi 4126 or aviscumine or axicabtagene ciloleucel or bafetinib or balamapimod or barsertib or bardoxolone or batabulin or batracylin or beclanorsen or beclin 1 or belapectin or belinostat or belizatinib or belvarafenib or belzupacap sarotalocan or belzutifan or bemcentinib or bempegaldesleukin or benfluron or bersanlimab or berzosertib or beta elemene or beta lapachone or bexarotene or bifikafusp alfa or bimiralisib or binimetinib or birabresib or biricodar or birinapant or bisnafide or bistratene or bomedemstat or borofalan b 10 or bortezomib or bosutinib or briciclib or brigatinib or brilanebrant or bropirimine or bryostatin or bullatacin or bullatacinone or buparlisib or cabazitaxel or calaspargase pegol or camelliin B or camidanlumab).mp.</p>
16	<p>(adagloxad simolenin or adegramotide or algenpantucel L or autogene cevumeran or axalimogene filolisbac or baloramotide or baltaleucel T or belagenpumatucel L or biropepimut S or bizalimogene ralaplasamid or cadalimogene ixalenticvec or dasiprotimut T or dorgenmeltucel L or eltrapuldencel T or falimarev or galinpepimut S or imm 101 or inalimarev or lapuleucel T or lovaxin b or maveropepimut S or mavilimogene ralaplasamid or mesmulogene ancovacicvec or mitumprotimut T or modified vaccinia virus Ankara 5T4 vaccine or relatimotide or nelipepimut S or olvimulogene nanivacirepvec or ombipepimut S or onamelatucel L or opolimogene capmilisbac or pemlimogene merolisbac or ranangengliotucel T or rasdegafusp alfa or rindopepimut or rocapuldencel T or rovaleucel or ruxotemitide or seviprotimut L or sipuleucel T or tecemotide or tergenpumatucel L or tertomotide or theratope or tipapkinogene sovacicvec or tisagenlecleucel T or vadacabtagene leraleucel or vesigenurtucel L or viagenpumatucel L or vitespen or zastumotide or canertinib or capivasertib or capmatinib or caracemide or carbetimer or carfilzomib or carlecortemcel L or carmethizole or ceclazepide or cedazuridine or cemadotin or cenersen or cenisertib or ceralasertib or cerdulatinib or cergutuzumab amunaleukin or ceritinib or cevipabulin or</p>

	<p>chloroquine or ciforadenant or ciltacabtagene autoleucel or cintirorgon or citarinstat or clervonafusp alfa or clofazimine or cobimetinib or cobomarsen or colloidal gold or combretastatin or conteltinib or contusugene ladenovec or copanlisib or corynebacterium parvum extract or crenigacestat or crisnatol or cryptophycin or curcumin or custirsen or cyclophosphamide plus doxorubicin plus taxane or cysteine ethyl ester methylcarbamate or cytostatic agent or cytotoxic agent or emtansine or mafodotin or mertansine or ravtansine or soravtansine or tafasitamab or dabrafenib or dacinostat or dacomitinib or dactolisib or damistimagene matitucel or danusertib or danvatirsen or daporinad or darinaparsin or darleukin or darolutamide or dasatinib or davamotecan pegadexamer or decernotinib or defactinib or degarelix or dehydroxymethylepoxyquinomicin or delanzomib or delimotecan or delolimogene mupadenorepvec or demethoxycurcumin or demplatin pegraglumer or denileukin diftitox or derazantinib).mp.</p>
17	<p>(azintuxizumab or balstilimab or belantamab or bemarituzumab or benufutamab or bexmarilimab or bintrafusp alfa or bivatuzumab or blinatumomab or blontuvetmab or brentuximab vedotin or brontictuzumab or budigalimab or camrelizumab or cantuzumab or catumaxomab or cemiplimab or cergutuzumab or cetrelimab or cetuximab or cevostamab or cibisatamab or cinrebausp alfa or cixutumumab orclivatuzumab tetraxetan or cobolimab or codrituzumab or cofetuzumab or coltuximab or conatumumab or cosibelimab or cudarolimab or cusatuzumab or dacetuzumab or dalotuzumab or daratumumab or datopotamab or demcizumab or demupitamab or denintuzumab or denosumab or depatuxizumab or derlotuximab biotin i 131 or detumomab or dilpacimab or dinutuximab or disitamab or dostarlimab or drozitumab or duligotuzumab or durvalumab or dusigitumab or duvortuxizumab or ecomeximab or edrecolomab or efizerimod alfa or elgemtumab or elotuzumab or emactuzumab or emibetuzumab or enapotamab or enavatuzumab or encelimab or enfortumab or enoblituzumab or enoticumab or ensituximab or envafolimab or eporitamab or epitumomab or epratuzumab or ertumaxomab or etaracizumab or ezabenlimab or farletuzumab or feladilimab or felzartamab or fianlimab or ficlatuzumab or figitumumab or flavotuzumab or flotetuzumab or fresolimumab or futuximab or galiximab or gancotamab or ganitumab or gatipotuzumab or gatrallimab or giloralimab or gilvetmab or girentuximab or glembatumumab or glofitamab or hyaluronidase plus rituximab or hyaluronidase plus trastuzumab or ibritumomab tiuxetan or icrucumab or ieramylimab or ifabotuzumab or iladatuzumab or imalumab or imgatuzumab or immunoliposome or immunotoxin or anatumomab mafenatox or cintredekin besudotox or citatuzumab bogatox or moxetumomab pasudotox or nacolomab tafenatox or naptumomab estafenatox or taplitumomab paptox or telimomab aritox or indatuximab or indusatumab or inebilizumab or intetumumab or ipilimumab or iratumumab or isatuximab or istiratumab or ivuxolimab or labetuzumab or lacnotuzumab or lacutamab or ladiratuzumab or laprituximab or lenzilumab or lexatumumab or lifastuzumab or lilotomab or lintuzumab or lililumab or lodapolimab or loncastuximab or lorukafusp alfa or lorvotuzumab or losatuxizumab or lucatumumab or lumiliximab or lumretuzumab or lupartumab or magrolimab or manelimab or mapatumumab or margetuximab or matuzumab or mavezelimab or mezagitamab or milatuzumab or minretumomab or miptenalimab or mirvetuximab or mirzotamab or mitumomab or modakafusp alfa or modotuximab or mogamulizumab or monalizumab).mp.</p>
18	<p>(deruxtecan or devimistat or dexniguldipine or dexverapamil or dezapelisib or diacetyldianhydrogalactitol or diaspirin crosslinked haemoglobin or didemethoxycurcumin or diglycoaldehyde or dihydroambazone or dilanubicel or dinaciclib or dinaline or discodermolide or disufenton sodium or ditercalinium or docetaxel or dociparstat or dofequidar or dolastatin or domatinostat or dubermatinib or dulanermin or duvelisib or ebifuramin or edelfosine or edicotinib or edotecarin or edotreotide ga 68 or edotreotide lu 177 or edotreotide y 90 or efaprinermin alfa or efatutazone or efgivanermin alfa or efineptakin alfa or eflornithine or eftozanermin alfa or elacestrant or elacridar or elafibranor or elagolix or elesclomol or eleutherobin or elinafide or elisidepsin or eltanexor or empesertib or enasidenib or encequidar or encorafenib or enistimgene setitucel or ensartinib or entasobulin or entinostat or entospletinib or entrectinib or enzastaurin or epertinib or epipodophyllotoxin or erbulozole or erdafitinib or eribulin or erlotinib or erucin or ethazolastone or etidaligide or everolimus or excicorilant or factor AF2 or fadraciclib or faldinamol or fedratinib or felezonexor or fenebrutinib or fenretinide or ferritin antibody i 131 or fetindomide or fibromun or filanesib or filgotinib or fimepinostat or fisogatinib or flavopiridol or flumatnib or fluorocyclopentenylcytosine or forodesine or fosciclopirox or fosquidone or fumitremorgin C or futibatnib or gallium nitrate or galunisertib or gandotinib or gataparsen or gedatolisib or gefitinib or geiparvarin or gendicine or gene expression modulator 231 or ghilanten or gilteritinib or girolline or givinostat or glasdegib or glucopyranosyl lipid A or glycoprotein P inhibitor or golnerminogene pradenovec or golvatinib or goniofufurone or granulocyte macrophage colony stimulating factor vaccine or grifolan or guanazole or gusacitinib or halichondrin B or heat shock protein 27 inhibitor or apatorsen or heat shock protein 90 inhibitor or alvespimycin or celastrol or gambogic acid or gamendazole or ganetespi or geldanamycin or</p>

	luminespib or onalespib or pimitespib or retaspimycin or tanespimycin or hepsulfam or HER dimerization inhibitor or hexamethylenebisacetamide or hydroxymethylpentamethylmelamine or hydroxyurea or hypericin or hypothemycin or iadademstat or ibrutinib or icotinib or idasanutlin or idecabtagene vicleucel or idelalisib or idetrexed or idronoxil or ilixadencel or ilmofosine or ilorasertib or imaradenant or imatinib or imetelstat or imlatoclast or abagovomab or abituzumab or actimab a or adebreliumab or adecatumumab or alacizumab pegol or alemtuzumab or alsevalimab or amatuximab or amivantamab or andecaliximab or anetumab or apolizumab or aprutumab or aprutumab ixadotin or ascrinvacumab or astegolimab or atezolizumab or avdoralimab or avelumab or axatilimab).mp.
19	(monoclonal antibody J591 or mosunetuzumab or murlentamab or nadunolimab or naratuximab or narnatumab or naxitamab or necitumumab or nesvacumab or nimotuzumab or nivolumab or nurulimab or obinutuzumab or ocaratuzumab or odronextamab or ofatumumab or olaratumab or oleclumab or olinvacimab or omburtamab or onartuzumab or ontuxizumab or onvatilimab or oportuzumab monatox or opucolimab or oregovomab or otlertuzumab or pacmilimab or panitumumab or parsatuzumab or pasotuxizumab or patritumab or pembrolizumab or pentumomab or pepinemab or pertuzumab or petosemtamab or pidilizumab or pimurutamab or pinatuzumab vedotin or plamotamab or polatuzumab vedotin or praluzatamab or pritumumab or prolgolimab or quavonlimab or racotumomab or radretumab or ragifilimab or ramucirumab or rasdegafusp alfa or relatlumab or retifanlimab or revdofilimab or rilatumumab or ripertamab or rituximab or robatumumab or rolinsatamab or rosmantuzumab or rosopatamab or rovalpituzumab or rovalpituzumab tesirine or sabatolimab or sacituzumab or samalizumab or samrotamab or sasanlimab or selicrelumab or serclutamab or seribantumab or serplulimab or sibrotuzumab or siltuximab or simlukafusp alfa or simtuzumab or sintilimab or sirtratumab or sofituzumab or solitomab or sontuzumab or spartalizumab or sugemalimab or tabalumab or tabituximab or tacatuzumab or tetraxetan yttrium y 90 or tacatuzumab y 90 or tafasitamab or talacotuzumab or talquetamab or tamrintamab or tamtuvetmab or tarextumab or tavolimab or tebotelimab or teclistamab or telisotuzumab or tenatumomab or tepoditamab or teprotumumab or tetulomab tetraxetan lutetium lu 177 or ticilimumab or tidutamab or tigatuzumab or tilogotamab or tilvestamab or timigutuzumab or tinurilimab or tiragolumab or tislelizumab or tisotumab or tomuzotuximab or toralizumab or toripalimab or tositumomab or tovetumab or trastuzumab or ublituximab or ulocuplumab or upifitamab or urabrelimab or urelumab or utomilumab or vadastuximab or vandortuzumab vedotin or vantiatumab or vanucizumab or varlilumab or veltuzumab or vesencumab or vibecotamab or vibostolimab or vofatamab or vonlerolizumab or vopratelimab or vorsetuzumab or vulinacimab or xentuzumab or zalifrelimab or zalutumumab or zanidatamab or zanolimumab or zolbetuximab or zuberitamab).mp.
20	(inavolisib or inbakicept or incyclinide or indibulin or indisulam or indoximod or ingenol disoxate or ingenol mebutate or inodiftagene vixteplasmid or interferon regulatory factor 2 or intiquinatin or intoplicine or ipafricept or ipatasertib or irosustat or isoswinholide A or ispinesib or itacitinib or itraconazole or ivaltinostat or ivosidenib or ixazomib or kahalalide F or krestin or laetrile or laniquidar or lapachol or lapatinib or lapretolimod or larifan or larotaxel or larotrectinib or laulimalide or lefitolimod or lerociclib or lestaurtinib or letetresgene autoleucel or lexidronam samarium sm 153 or lifileucel or lifirafenib or linperlisib or linrodostat or lisocabtagene maraleucel or litenimod or litronesib or lonafarnib or lonidamine or lorlatinib or ltvax or lurtotecan or maltose tetrapalmitate or masitinib or mavelertinib or mavorixafor or melacine or merbarone or merestinib or methanol extraction residue or metirosine or mevociclib or midostaurin or mifamurtide or milademetan or milataxel or milciclib or miltefosine or mipetresgene autoleucel or mipsagargin or miralimogene ensolisbac or miransertib or mirdametinib or mirostipen or mitazalimab or mitindomide or mitobronitol or mitoflaxone or mitoguazone or mitolactol or mitonafide or mitoquidone or mitotane or mitozolomide or mivavotinib or mivebresib or mivobulin or mobocertinib or mocemestocel or mocetinostat or molibresib or momelotinib or monastrol or mosedipimod or motixafortide or motolimod or mubritinib or mucocin or murizatoclast or mycalamide or myeloablative agent or nabiximols or nadofaragene firadenovec or namodenoson or nanatinostat or napabucasin or naquotinib or nastorazepide or navitoclax or navoximod or nazartinib or necuparanib or nemiralisib or neratinib or netazepide or nevanimibe or nilotinib or niraparib or nirogacestat or nitracrine or nitrocaphane or noscapine or numidargistat or nutlin or obafistat or obatoclax or oblimersen or oblongifolin C or oblongixanthone A or obovatal or obtusilactone A or oclacitinib or olafertinib or olaparib or olaptosed pegol or olcorolimus or olitresgene autoleucel or olmutinib or olutasidenib or olverembatinib or omidubicel or omipalisib or omtriprotide or onatasertib or oncolytic virus or oncolytic adenovirus or enadenotucirev or lontucirev or tasadenoturev or oncolytic herpes virus or canerptarev or seprehvir or talimogene laherparepvec or tesarptarev or oncolytic paramyxovirus or oncolytic parvovirus or oncolytic reovirus or pelareorep or pexastimogene devacirepvec or onfekafusp alfa or ontorpcept or onvansertib or opaganib or opigolix or oprozomib or oracin or orelabrutinib or

	<p>ortataxel or orvacabtagene autoleucel or osimertinib or oxamflatin or oxodotreotide lu 177 or paclitaxel ceribate or paclitaxel derivative or paclitaxel poliglumex or paclitaxel tocosol or paclitaxel trevatide or pacritinib or palbociclib or palmerolide A or pamiparib or panaxytriol or panduratin A or panobinostat or panulisib or parsacalisib or pasireotide or paxalisib or pegargiminase or pegcantratinib or pegcrisantaspase or pegilodecakin or pegvorhyaluronidase alfa or pelcitolclax or pelidotin or pelitinib or pemigatinib or penclomedine or peposertib or peretinoin).mp.</p>
21	<p>(perifosine or pevonedistat or pexidartinib or phenethyl isothiocyanate or phomopsin A or phorbaxazole or phyllanthocin or phyllanthoside or picibanil or pictilisib or pilaralisib or pimasertib or pinometostat or pipobroman or pivaloyloxymethyl butyrate or plocabulin or plusonermin or podophyllotoxin or polyerga or ponatinib or poziotinib or pracinostat or pralsetinib or prexasertib or prexigebersen or prospidium or ptilocaulin or pyran copolymer or pyrazine diazohydroxide or quarfloxin or quisinostat or quizartinib or rabacfosadine or rabusertib or radiosensitizing agent or radio-sensitizing agent or bromodeoxycytidine or broxuridine or chloroaluminum phthalocyanine or cloxuridine or crocetin ordeclopramide or doranidazole or efaproxiral or etanidazole or etiopurpurin or fimaporfin or gadolinium texaphyrin or gilvocarcin V or hematoporphyrin derivative or isometronidazole or lemuteporfin or lutetium texaphyrin or merocyanine or misonidazole or motexafin or napavin or nimorazole or nocodazole or normisonidazole or padeliporfin or padoporfin or photofrin I or photofrin II or photosan III or phthalocyanine or pimonidazole or porfimer or redaporfin or senazole or talaporfin or temoporfin or tetrachloroplatinum fast black or tetraphenylporphyrin or tetrasulfophthalocyanine or tirapazamine or tretazicar or troquidazole or verteporfin or radium chloride ra 223 or radotinib or ralimetinib or ranpirnase or rapamycin or ravoxertinib or razoxane or rebastinib or recombinant asparaginase or recombinant interleukin 21 or denenicokin or recombinant methionine gamma lyase or recombinant tumor necrosis factor related apoptosis inducing ligand or refametinib or remetinostat or repotrectinib or resminostat or rezivertinib or rhizoxin or rhodamine 6G or ribociclib or ribonucleotide reductase R2 specific phosphorothioate oligonucleotide or ricolinostat or ridafolorimus or rigosertib or rilimogene galvacirepvec or rilimogene glafolivec or ripretinib or riviciclib or rivogenlecleucel or robaveron or roblitinib or rocakinogene sifuplasmid or rociletinib or roniciclib or roridin A or rosabulin or rosomidnar or rucaparib or ruxolitinib or salinosporamide A or salirasib or samotolisib or samuraciclib or sapanisertib or sapitinib or saracatinib or sarcodictyin A or sarcophytol A or sarcophytol B or sardomozide or satoreotide trizoxetan or savolitinib or Sclerotinia sclerotiorum extract or seclidemstat or selectikine or selinexor or selitrectinib or selpercatinib or selumetinib or seocalcitol or sepantronium bromide or serabelisib or serdemetan or serpentine or shikonin derivative or silmitasertib or simotaxel or simurosertib or siremadlin or sitimagene ceradenovec or sitravatinib or sobuzoxane or solcoderm or sonermin or sonidegib or sonolisib or sparfosic acid or spebrutinib or spirobromine or squamocin or ssioriside or stapuldencel T or starch microsphere or sulfatinib or sulfuraphane or sulindac sulfone or sulofenur or suramin or swinholide A or swinholide B).mp.</p>
22	<p>(tacedinaline or tafluposide or tagraxofusp or talabostat or talactoferrin or taladegib or talazoparib or talirine or taltobulin or tamibarotene or taminadenant or tandutinib or tanshinone IIA or tanurmotide or tariquidar or tarloxotinib or tasislisib or tasidotin or tasisulam or tasonermin or tavokinogene telseplasmid or tazemetostat or tebentafusp or tebocabtagene autoleucel or tecogalan or tefinostat or tegavivint or teglarinad chloride or telaglenastat or teleukin or telomestatin or telotristat or telratolimod or temarotene or temsirolimus or tenalisib or tengonermin or tepotinib or teprasiran or terameprocol or teroxirone or tesetaxel or tetramethylmelamine or tetravil or thioglucose or tian xian wan or tigilanol tiglactate or tilomisole or tilsotolimod or timcodar or timonacic derivative or tipifarnib or tirabrutinib or tivantinib or tomivosertib or topsalysin or tosedostat or tozasertib or trametinib or transferrin aldifitox or trichlormethine or trichosanthin or trichostatin A or triciribine or triciribine phosphate or trilaciclib or trimelamol or tubacin or tubulozole or tucatinib or tucidinostat or tucotuzumab celmoleukin or tumor suppressor protein or inhibitor of growth protein 1 or ubiquitin carboxyl terminal hydrolase CYLD or tuvateixib or tylophorine or ulicyclamide or ulipristal or ulithiacyclamide or ulixertinib or umbralisib or upamostat or uproleselan or uprosertib or uzansertib or vaccinia oncolysate or vactosertib or valecobulin or valemestostat or valsopodar or varlitinib or vascular targeting agent or anginex or bavtuximab or crolibulin or denibulin or lexibulin or n acetylcolchinol phosphate or ofranergene obadenovec or ombrabulin or plinabulin or soblidotin or vadimezan or vecabrutinib or vedotin or velimogene aliplasmid or veliparib or vemurafenib or venetoclax or verdinexor or verrucarin A or verubulin or vesatolimod or virus oncolysate or vismodegib or vistusertib or vocimagene amiretorepvec or volasertib or vorasidenib or vorinostat or voruciclib or vosaroxin or vosilasarm or voxalisib or withaferin A or WW domain containing oxidoreductase or xanthone 4 acetic acid or xevinapant or xiaochaihu tang or xiliertinib or zafiride or zandelisib or zanubrutinib or</p>

	zenocutuzumab or zerumbone or zibotentan or zilascorb or zoledronic acid or zoligratinib or zorifertinib or zosuquidar or zotatifin or zotiraciclib).mp.
23	(protein tyrosine kinase inhibitor or tyrosine kinase inhibitor or tyrosine protein kinase inhibitor or anaplastic lymphoma kinase inhibitor or bruton tyrosine kinase inhibitor or adaphostin or alofanib or alpha cyanothiocaffaic acid amide or altiratinib or alvespimycin or amivantamab or amuvatinib or alectinib or brigatinib or ceritinib or crizotinib or ensartinib or entrectinib or lorlatinib or repotrectinib or asciminib or avapritinib or axitinib or bafetinib or belizatinib or bemcentinib or bosutinib or brivanib or brivanib alaninate or acalabrutinib or branebrutinib or dasatinib or elsubrutinib or evobrutinib or ibrutinib or orelabrutinib or poselatinib or remibrutinib or rilzabrutinib or spebrutinib or tolebrutinib or vecabrutinib or zanubrutinib or cabozantinib or capmatinib or catequentinib or cediranib or cerdulatinib or cevidoplenib or conteltinib or crenolanib or damnacanthol or decernotinib or defactinib or derazantinib or dovitinib or dubermatinib or edicotinib or elafibranor or emodin or epidermal growth factor receptor kinase inhibitor or erbstatin or focal adhesion kinase inhibitor or Janus kinase inhibitor or baricitinib or brepocitinib or delgocitinib or fedratinib or fosifidancitinib or gusacitinib or ifidancitinib or ilginatinib or itacitinib or izencitinib or abrocitinib or filgotinib or lorpucitinib or momelotinib or ruxolitinib or tofacitinib or upadacitinib or lavendustin A or lazertinib or linsitinib or lorecivivint or mitogen activated protein kinase kinase inhibitor or peficitinib or pexmetinib or protein kinase Syk inhibitor or fostamatinib or lanraplenib or piceatannol or radicicol or recifercept or ritlecitinib or seralutinib or solcitinib or suppressor of cytokine signaling 1 or telatinib or tilvestamab or tyrphostin).mp.
24	(abscopal effect or bone marrow purging or bone marrow rescue or chemoradiotherap* or chemoradiation or antibody directed enzyme prodrug therap* or chemoembolization or graft versus tumo?r effect or graft versus leuk?emia effect or graft versus lymphoma effect or oncolytic viral therap* or oncolytic virus therap* or target cell destruction or biologic* response modifier therap* or BRM therap* or chimeric antigen receptor immunotherap* or chimeric antigen receptor natural killer cell immunotherap* or chimeric antigen receptor T-cell immunotherap* or CAR immontherap* or CAR T cell therap* or CAR T cell immunotherap* or CAR T therap* or CAR NK cell immunotherap* or CAR NK cell therap* or chimeric antigen receptor T cells or immune checkpoint inhibitor* or immune checkpoint blockade* or radioimmunotherap* or immunoradiotherap* or radiotherap* or bioradiant therap* or hemibody irradiation or irradiation therap* or irradiation treatment* or radiation therap* or radiation treatment* or radio therap* or radiotreatment or beam therap* or blood radiation or brachytherap* or interstitial radiation or radioisotope therap* or radium therap* or electron therap* or gamma irradiation or gamma knife radiosurgery or body radiation or photon beam therap* or proton beam therap* or radioimmunotherap* or stereotactic radiosurgery or teleradiotherap* or bone marrow transplant* or bone marrow cell transfer or bone marrow graft* or bone marrow transfusion* or h?ematopo?etic stem cell* or HSC therap* or HSC transplant* or stem cell transplant* or stem cell based therap* or stem cell therap* or allogeneic stem cell* or autologous stem cell* or peripheral blood stem cell* or allogen?ic HSCT or allogen?ic HSCTs or auto-HSCT or auto-HSCTs or autologous HSCT or autologous HSCTs or tumo?r killing activit* or tumo?r killing effect* or tumo?r killing action* or log cell kill or metastatic* inhibit* or metastas* inhibit*).mp.
25	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26	blood vessel parameters/ or arterial stiffness/ or arterial wall thickness/ or artery diameter/ or augmentation index/ or blood vessel diameter/ or carotid-femoral pulse wave velocity/ or endothelial dysfunction/ or artery compliance/ or blood vessel compliance/ or vascular remodeling/ or artery blood flow/ or pulse wave/ or blood vessel function/ or blood vessel reactivity/ or vascular resistance/ or vasoconstriction/ or vasodilatation/ or vascular endothelium/ or artery endothelium/ or artery dilatation/ or blood flow velocity/ or blood vessel capacitance/
27	(tunica intima/ or endothelium, vascular/ or tunica media/ or muscle, smooth, vascular/ or Endothelial Cells/) and (cellular senescence/ or telomere shortening/ or Aging/)
28	arteriosclerosis/ or arteriolosclerosis/ or artery intima proliferation/
29	(endothelial function or endothelial vascular function).mp.
30	((vascular* or vasculature or endotheli* or vessel*) adj4 (ag?ing or aged or stiff* or dysfunction* or impair* or deficit* or defect* or change* or alteration* or remodel?ing or dilat* or degenerat* or thick* or elasticit* or elastance or distens*).mp.
31	((vascular* or vasculature or endotheli* or blood vessel*) adj (inflammation or senescen* or cell senescence or damage or dyshomeostasis or measurement* or compliance or calcification or reactivity)).mp.

32	((artery or arteries or arteria* or aorta* or aortic*) adj4 (ag?ing or stiff* or thick* or compliance or distens* or wave reflection or reflection index or elasticit* or elastance or defect* or change* or impair* or diameter* or dilat* or measurement* or dysfunction* or alteration* or remode?ling or calcification)).mp.
33	((Intima* media* or intimamedia* or tunica intima or tunica media) adj3 thick*).mp.
34	(pressure wave transmission or pressure wave reflection or pulse pressure or pulse wave velocity or pulse wave analys#s or pulse wave amplitude or arterial pulsatility or flow mediated dilation or blood flow velocit* or arter* flow velocit*).mp.
35	(aortic blood pressure* or aortic pressure* or aortic pulse pressure* or aortic tension* or central aortic blood pressure* or central aortic pressure*).mp.
36	(central BP or arterial BP or aortic BP or (central SBP or arterial SBP or aortic SBP) or (central PP or arterial PP or aortic PP)).mp.
37	(aortic blood pulse wave* or aortic pulse wave* or aortic tension* or arterial blood pulse wave* or arterial pulse wave* or arterial tension* or central aortic blood pulse wave* or central aortic pulse wave* or carotid to femoral pulse wave* or pulse wave*).mp.
38	(augmentation adj (index* or indice*)).mp.
39	((augmentation or amplification) adj6 (pressure* or pulse* or wave* or aortic or central)).mp.
40	26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41	25 and 40
42	clinical trial/ or randomized controlled trial/ or randomization/ or single blind procedure/ or double blind procedure/ or crossover procedure/ or placebo/ or prospective study/
43	(randomi?ed controlled or RCT or randomly allocated or allocated randomly or random allocation or (allocated adj2 random) or (single adj1 blind*) or (double adj1 blind*) or ((treble or triple) adj1 blind*) or placebo*).mp.
44	((cross-sectional or prevalence or disease frequency) adj (analys#s or study or studies or survey)).mp.
45	((cohort or incidence) adj (analys#s or study or studies or survey)).mp.
46	((follow-up or followup or longitudinal or prospective or retrospective) adj (study or studies)).mp.
47	42 or 43 or 44 or 45 or 46
48	41 and 47
49	(exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not exp human/
50	48 not 49
51	limit 50 to english language
52	limit 51 to (editorial or letter or note)
53	51 not 52
54	53 not (case report* or news or newspaper*).mp.pt.
55	limit 54 to conference abstract
56	54 not 55
57	limit 56 to conference abstracts
58	56 not 57

#	Query
S15	S11 OR S13 Limiters - Publication Year: 1990-2020; English Language; Exclude MEDLINE records
S14	S11 OR S13
S13	S5 AND S12
S12	((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) N4 (accessibility or availability))) OR (((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) N0 (need* or demand*))) OR (((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*)) N2 (need* or demand*)))
S11	S9 AND S10
S10	(readiness or preparedness or capacity or quality improvement or quality of Improvement)
S9	S5 AND S8
S8	S6 OR S7
S7	((primary health system or primary health service or primary healthcare system or primary health care system or primary healthcare service or primary health care service or primary medical service delivery or primary medical care service or primary care service or primary care system)) OR ((first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) OR (((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*)))
S6	(MH "Primary Health Care") OR (MH "Health Care Delivery")
S5	S1 OR S2 OR S3 OR S4
S4	((diastolic pressure or systolic pressure or blood pressure or cardiometabolic syndrome*)) OR ((copd or asthma or renal disease* or kidney disease*))
S3	((cardiovascular disease* or coronary artery disease* or myocardial isch?emia or myocardial infarct* or pulmonary disease* or chronic obstructive pulmonary or chronic obstructive lung or chronic obstructive respiratory or diabetes or coronary heart disease* or neoplasm* or cancer*)) OR ((hypertension or hypertriglycerid?emi* or hyper triglycerid?emi* or high triglyceride* or high cholesterol or hypercholesterol?emi* or hyperlipid?emia* or hyperlipidemi*))
S2	((chronic disease* or chronic disorder* or chronic* sick* or chronic health condition* or chronic medical condition* or chronic* ill* or long term condition* or multimorbidit* or mult imorbidit*)) OR ((non-communicable disease* or non-infectious disease* or noncommunicable disease* or noninfectious disease*))
S1	(MH "Chronic Disease") OR (MH "Noncommunicable Diseases") OR (MH "Chronic Pain")

CINAHL Search

Database(s): APA PsycInfo
Search Strategy:

#	Searches	Results
1	chronic illness/ or chronic fatigue syndrome/ or chronic pain/	27358
2	(chronic disease* or chronic disorder* or chronic* sick* or chronic health condition* or chronic medical condition* or chronic* ill* or long term condition* or multimorbidit* or mult imorbidit*).mp.	48956
3	(non-communicable disease* or non-infectious disease* or noncommunicable disease* or noninfectious disease*).mp.	1052
4	(cardiovascular disease* or coronary artery disease* or myocardial isch?emia or myocardial infarct* or pulmonary disease* or chronic obstructive pulmonary or chronic obstructive lung or chronic obstructive respiratory or diabetes or coronary heart disease* or neoplasm* or cancer*).mp.	121105
5	(hypertension or hypertriglycerid?emi* or hyper triglycerid?emi* or high triglyceride* or high cholesterol or hypercholesterol?emi* or hyperlipid?emia* or hyperlipidemi*).mp.	20201
6	(diastolic pressure or systolic pressure or blood pressure or cardiometabolic syndrome*).mp.	24127
7	(copd or asthma or renal disease* or kidney disease*).mp.	13056
8	1 or 2 or 3 or 4 or 5 or 6 or 7	207978
9	primary health care/	18474
10	health care delivery/	20844
11	(primary health system or primary health service or primary healthcare system or primary health care system or primary healthcare service or primary health care service or primary medical service delivery or primary medical care service or primary care service or primary care system).mp.	511
12	(first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*).mp.	338
13	((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*)).mp.	2322
14	9 or 10 or 11 or 12	38723
15	8 and 14	4987
16	(readiness or preparedness or capacity or quality improvement or quality of Improvement).mp.	118317
17	15 and 16	312
18	((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) adj5 (accessibility or availability)).mp.	148
19	8 and 18	19
20	((primary care or primary health care or primary healthcare or primary health system* or primary medical service* or primary medical care or (first-level healthcare or first-level health care or first-level health system* or first-level health facilit* or local health system* or local health care or local healthcare or local-level health*)) adj (need* or demand*).mp.	290
21	8 and 20	55
22	((primary or first-level or local) adj3 health* adj3 (clinic* or center* or centre* or setting*) adj3 (need* or demand*)).mp.	17
23	8 and 22	2
24	17 or 19 or 21 or 23	387

25	limit 24 to english language	380
26	limit 25 to yr="1990 -Current"	380
27	limit 26 to ("column/opinion" or "comment/reply" or dissertation or editorial or letter)	41
28	26 not 27	339

Scopus

Search Strategy:

(((((TITLE-ABS-KEY(("chronic disease*" OR "chronic disorder*" OR "chronic* sick*" OR "chronic health condition*" OR "chronic medical condition*" OR "chronic* ill*" OR "long term condition*" OR multimorbidit* OR "mult imorbidit*")))) OR (TITLE-ABS-KEY(("non-communicable disease*" OR "non-infectious disease*" OR "noncommunicable disease*" OR "noninfectious disease*")))) OR (TITLE-ABS-KEY(("cardiovascular disease*" OR "coronary artery disease*" OR "myocardial isch?emia" OR "myocardial infarct*" OR "pulmonary disease*" OR "chronic obstructive pulmonary" OR "chronic obstructive lung" OR "chronic obstructive respiratory" OR diabetes OR "coronary heart disease*" OR neoplasm* OR cancer*))) OR (TITLE-ABS-KEY(("hypertension OR hypertriglycerid?emi* OR "hyper triglycerid?emi*" OR "high triglyceride*" OR "high cholesterol" OR hypercholesterol?emi* OR hyperlipid?emia* OR hyperlipidemi*))) OR (TITLE-ABS-KEY(("diastolic pressure" OR "systolic pressure" OR "blood pressure" OR "cardiometabolic syndrome*")))) OR (TITLE-ABS-KEY(("copd OR asthma OR "renal disease*" OR "kidney disease*")))) AND (((TITLE-ABS-KEY(("primary health system" OR "primary health service" OR "primary healthcare system" OR "primary health care system" OR "primary healthcare service" OR "primary health care service" OR "primary medical service delivery" OR "primary medical care service" OR "primary care service" OR "primary care system")))) OR (TITLE-ABS-KEY(("first-level healthcare" OR "first-level health care" OR "first-level health system*" OR "first-level health facilit*" OR "local health system*" OR "local health care" OR "local healthcare" OR "local-level health*")))) OR (TITLE-ABS-KEY(("primary OR "first-level" OR local) W/2 health* W/2 (clinic* OR center* OR centre* OR setting*)))) AND (TITLE-ABS-KEY(("readiness OR preparedness OR capacity OR "quality improvement" OR "quality of Improvement")))) OR (((TITLE-ABS-KEY(("chronic disease*" OR "chronic disorder*" OR "chronic* sick*" OR "chronic health condition*" OR "chronic medical condition*" OR "chronic* ill*" OR "long term condition*" OR multimorbidit* OR "mult imorbidit*")))) OR (TITLE-ABS-KEY(("non-communicable disease*" OR "non-infectious disease*" OR "noncommunicable disease*" OR "noninfectious disease*")))) OR (TITLE-ABS-KEY(("cardiovascular disease*" OR "coronary artery disease*" OR "myocardial isch?emia" OR "myocardial infarct*" OR "pulmonary disease*" OR "chronic obstructive pulmonary" OR "chronic obstructive lung" OR "chronic obstructive respiratory" OR diabetes OR "coronary heart disease*" OR neoplasm* OR cancer*))) OR (TITLE-ABS-KEY(("hypertension OR hypertriglycerid?emi* OR "hyper triglycerid?emi*" OR "high triglyceride*" OR "high cholesterol" OR hypercholesterol?emi* OR hyperlipid?emia* OR hyperlipidemi*))) OR (TITLE-ABS-KEY(("diastolic pressure" OR "systolic pressure" OR "blood pressure" OR "cardiometabolic syndrome*")))) OR (TITLE-ABS-KEY(("copd OR asthma OR "renal disease*" OR "kidney disease*")))) AND (TITLE-ABS-KEY(("primary care" OR "primary health care" OR "primary healthcare" OR "primary health system*" OR "primary medical service*" OR "primary medical care" OR "first-level healthcare" OR "first-level health care" OR "first-level health system*" OR "first-level health facilit*" OR "local health system*" OR "local health care" OR "local healthcare" OR "local-level

health*") W/4 (accessibility OR availability)))) OR (((TITLE-ABS-KEY (("chronic disease*" OR "chronic disorder*" OR "chronic* sick*" OR "chronic health condition*" OR "chronic medical condition*" OR "chronic* ill*" OR "long term condition*" OR multimorbidit* OR "mult imorbidit*")))) OR (TITLE-ABS-KEY (("non-communicable disease*" OR "non-infectious disease*" OR "noncommunicable disease*" OR "noninfectious disease*")))) OR (TITLE-ABS-KEY (("cardiovascular disease*" OR "coronary artery disease*" OR "myocardial isch?emia" OR "myocardial infarct*" OR "pulmonary disease*" OR "chronic obstructive pulmonary" OR "chronic obstructive lung" OR "chronic obstructive respiratory" OR diabetes OR "coronary heart disease*" OR neoplasm* OR cancer*)))) OR (TITLE-ABS-KEY ((hypertension OR hypertriglycerid?emi* OR "hyper triglycerid?emi*" OR "high triglyceride*" OR "high cholesterol" OR hypercholesterol?emi* OR hyperlipid?emia* OR hyperlipidemi*)))) OR (TITLE-ABS-KEY (("diastolic pressure" OR "systolic pressure" OR "blood pressure" OR "cardiometabolic syndrome*")))) OR (TITLE-ABS-KEY ((copd OR asthma OR "renal disease*" OR "kidney disease*")))) AND (TITLE-ABS-KEY (("primary care" OR "primary health care" OR "primary healthcare" OR "primary health system*" OR "primary medical service*" OR "primary medical care" OR "first-level healthcare" OR "first-level health care" OR "first-level health system*" OR "first-level health facilit*" OR "local health system*" OR "local health care" OR "local healthcare" OR "local-level health*") W/0 (need* OR demand*))))) OR (((TITLE-ABS-KEY (("chronic disease*" OR "chronic disorder*" OR "chronic* sick*" OR "chronic health condition*" OR "chronic medical condition*" OR "chronic* ill*" OR "long term condition*" OR multimorbidit* OR "mult imorbidit*")))) OR (TITLE-ABS-KEY (("non-communicable disease*" OR "non-infectious disease*" OR "noncommunicable disease*" OR "noninfectious disease*")))) OR (TITLE-ABS-KEY (("cardiovascular disease*" OR "coronary artery disease*" OR "myocardial isch?emia" OR "myocardial infarct*" OR "pulmonary disease*" OR "chronic obstructive pulmonary" OR "chronic obstructive lung" OR "chronic obstructive respiratory" OR diabetes OR "coronary heart disease*" OR neoplasm* OR cancer*)))) OR (TITLE-ABS-KEY ((hypertension OR hypertriglycerid?emi* OR "hyper triglycerid?emi*" OR "high triglyceride*" OR "high cholesterol" OR hypercholesterol?emi* OR hyperlipid?emia* OR hyperlipidemi*)))) OR (TITLE-ABS-KEY (("diastolic pressure" OR "systolic pressure" OR "blood pressure" OR "cardiometabolic syndrome*")))) OR (TITLE-ABS-KEY ((copd OR asthma OR "renal disease*" OR "kidney disease*")))) AND (TITLE-ABS-KEY (("primary OR "first-level" OR local) W/2 health* W/2 (clinic* OR center* OR centre* OR setting*) W/2 (need* OR demand*))))) AND (LIMIT-TO (LANGUAGE , "English")) AND (EXCLUDE (DOCTYPE , "ch") OR EXCLUDE (DOCTYPE , "no") OR EXCLUDE (DOCTYPE , "bk") OR EXCLUDE (DOCTYPE , "ed")) AND (EXCLUDE (SUBJAREA , "AGRI") OR EXCLUDE (SUBJAREA , "CENG") OR EXCLUDE (SUBJAREA , "ARTS") OR EXCLUDE (SUBJAREA , "BUSI") OR EXCLUDE (SUBJAREA , "EART") OR EXCLUDE (SUBJAREA , "VETE"))) View less

Table S2. A list of the excluded studies and reasons for their exclusion

SL	Study	Reason for exclusion
01	Abolhassani N, Santos-Eggimann B, Chiolero A, Santschi V, Henchoz Y. Readiness to accept health information and communication technologies: A population-based survey of community-dwelling older adults. <i>International Journal of Medical Informatics</i> 2019; 130 : 103950.	Not relevant to the theme for review
02	Acton KJ, Shields R, Rith-Najarian S, et al. Applying the diabetes quality improvement project indicators in the Indian Health Service primary care setting. <i>Diabetes Care</i> ; 24 (1): 22-6.	Inadequate or inappropriate results
03	Ahmed S, Chowdhury MA, Khan MA, Huq NL, Naheed A. Access to primary health care for acute vascular events in rural low income settings: a mixed methods study. <i>BMC Health Services Research</i> ; 17 (1): 47.	Inadequate or inappropriate results
04	Allenby A, Kinsman L, Tham R, Symons J, Jones M, Campbell S. The quality of cardiovascular disease prevention in rural primary care. <i>Australian Journal of Rural Health</i> ; 24 (2): 92-8.	Inadequate or inappropriate results
05	Armour CL, Reddel HK, Lemay KS, et al. Feasibility and Effectiveness of an Evidence-Based Asthma Service in Australian Community Pharmacies: A Pragmatic Cluster Randomized Trial. <i>Journal of Asthma</i> 2013; 50 (3): 302-9.	Not relevant to the theme for review
06	Alzubaidi HT, Chandir S, Hasan S, McNamara K, Cox R, Krass I. Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: A feasibility study.	Inadequate or inappropriate results
07	Ahmedov M, Green J, Azimov R, Avezova G, Inakov S, Mamatkulov B. Addressing the challenges of improving primary care quality in Uzbekistan: a qualitative study of chronic heart failure management. <i>Health Policy & Planning</i> ; 28 (5): 458-66.	Inadequate or inappropriate results
08	Aryal BK, Daud M, Thapa A, Mahotra A, Ale Magar S, Malla CK. Assessment of Health Facilities for Implementation of Non-communicable Disease Package. <i>Journal of Nepal Health Research Council</i> ; 16 (2): 149-55.	Combined data on primary and secondary healthcare level
09	Banasiak NC. Implementation of the Asthma Control Test in Primary Care to Improve Patient Outcomes. <i>Journal of Pediatric Healthcare</i> 2018; 32 (6): 591-9.	Not relevant to the theme for review
10	Barcelos MRB, Nunes BP, Duro SMS, et al. Utilization of Breast Cancer Screening in Brazil: An External Assessment of Primary Health Care Access and Quality Improvement Program.	Not relevant to the theme for review
11	Bello AK, Ronksley PE, Tangri N, et al. Quality of Chronic Kidney Disease Management in Canadian Primary Care. <i>JAMA Network Open</i> ; 2 (9): e1910704.	Inadequate or inappropriate results
12	Baeza JI, Fitzgerald L, McGivern G. Change capacity: the route to service improvement in primary care. <i>Quality in Primary Care</i> ; 16 (6): 401-7.	Inadequate or inappropriate results
13	Bawazir AA, Al-Surimi K, Suwaidan SD, AlShehri AM, AlFarhan AI, Aboufotouh MA. Capacity and readiness of primary health care centers for implementation of the basic strategy for prevention and control of non-communicable diseases in Saudi Arabia. A case study from the Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. <i>Saudi Medical Journal</i> ; 40 (6): 614-8.	Inappropriate study type (n=1)
14	Boehmer KR, Kyriacou M, Behnken E, Branda M, Montori VM. Patient capacity for self-care in the medical record of patients with	Not relevant to the theme for review

	chronic conditions: a mixed-methods retrospective study. <i>BMC family practice</i> 2018; 19 (1): 164.	
15	Bindman AB, Grumbach K, Osmond D, Vranizan K, Stewart AL. Primary care and receipt of preventive services.	Inadequate or inappropriate results
16	Birabwa C, Bwambale MF, Waiswa P, Mayega RW. Quality and barriers of outpatient diabetes care in rural health facilities in Uganda - a mixed methods study. <i>BMC Health Services Research</i> ; 19 (1): 706.	Combined data on primary and secondary healthcare level
17	Brownson CA, Miller D, Crespo R, et al. A quality improvement tool to assess self-management support in primary care. <i>Joint Commission Journal on Quality & Patient Safety</i> ; 33 (7): 408-16.	Inadequate or inappropriate results
18	Casalino LP, Wu FM, Ryan AM, et al. Independent practice associations and physician-hospital organizations can improve care management for smaller practices. <i>Health Affairs</i> ; 32 (8): 1376-82.	Inadequate or inappropriate results
19	Chavannes NH. Integrated chronic obstructive pulmonary disease management in primary care. <i>Disease Management & Health Outcomes</i> 2008; 16 (5): 315-8.	Inadequate or inappropriate results
20	Chen M, Patel T, Chang F. The impact of a primary care, pharmacist-driven intervention in patients with chronic non-cancer pain-A pilot study. <i>Pharmacy</i> 2020; 8 (8): 113.	Not relevant to the theme for review
21	Chen XRC, Leung SH, Li YC. Chronic Obstructive Pulmonary Disease (COPD) management in the community: how could primary care team contribute? <i>BMC family practice</i> 2020; 21 (1): 184.	Not relevant to the theme for review
22	Collins S. Primary care shortages: Strengthening this sector is urgently needed, now and in preparation for healthcare reform. <i>American Health and Drug Benefits</i> 2012; 5 (1): 40-7.	Inadequate or inappropriate results
23	Chen LW, Nguyen AT, Jacobson J, Palm D. Assessment of workforce capacity for Local Health Departments in Nebraska: a perspective from public health programmatic areas. <i>Journal of Public Health Management & Practice</i> ; 18 (6): 595-601.	Not relevant to the theme for review
24	Chen LM, Sakshaug JW, Miller DC, Rosland A-M, Hollingsworth J. The association among medical home readiness, quality, and care of vulnerable patients. <i>Am J Manag Care</i> 2015; 21 (8): e480-e6.	Inadequate or inappropriate results
25	Day A, Oldroyd C, Godfrey S, Quinn T. Availability of cardiac equipment in general practice premises in a cardiac network: A survey. <i>British Journal of Cardiology</i> 2008; 15 (3): 141-4.	Inadequate or inappropriate results
26	Deckard GJ, Borkowski N, Diaz D, Sanchez C, Boissette SA. Improving timeliness and efficiency in the referral process for safety net providers: Application of the lean six sigma methodology. <i>Journal of Ambulatory Care Management</i> 2010; 33 (2): 124-30.	Not relevant to the theme for review
27	Depatie A, Bigbee JL. Rural Older Adult Readiness to Adopt Mobile Health Technology: A Descriptive Study. <i>Online Journal of Rural Nursing & Health Care</i> 2015; 15 (1): 150-84.	Inadequate or inappropriate results
28	Due TD, Thorsen T, Waldorff FB, Kousgaard MB. Role enactment of facilitation in primary care - a qualitative study. <i>BMC Health Services Research</i> ; 17 (1): 593.	Not relevant to the theme for review
29	Fleck S. Unified health services and family focused primary care.	Not relevant to the theme for review
30	Foo KM, Sundram M, Legido-Quigley H. Facilitators and barriers of managing patients with multiple chronic conditions in the community: a qualitative study. <i>BMC public health</i> 2020; 20 (1): 273.	Inadequate or inappropriate results
31	Fortin M, Chouinard M-C, Diallo BB, Bouhali T. Integration of chronic disease prevention and management services into primary care (PR1MaC): findings from an embedded qualitative study. <i>BMC Family Practice</i> 2019; 20 (1): 1-8.	Inadequate or inappropriate results

32	Fox CH, Brooks A, Zayas LE, McClellan W, Murray B. Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study. <i>Journal of the American Board of Family Medicine: JABFM</i> ; 19 (1): 54-61.	Not relevant to the theme for review
33	Fuchs S, Jaffe DM, Christoffel KK. Pediatric emergencies in office practices: prevalence and office preparedness. <i>Pediatrics</i> ; 83 (6): 931-9.	Not relevant to the theme for review
34	Furno M. The primary role: How the availability of primary care physicians affects diabetes care management.	Inadequate or inappropriate results
35	Galaviz KI, Narayan KMV, Manders OC, et al. The Public Health Leadership and Implementation Academy for Noncommunicable Diseases. <i>Preventing Chronic Disease</i> ; 16 : E49.	Inadequate or inappropriate results
36	Ghimire U, Shrestha N, Adhikari B, Mehata S, Pokharel Y, Mishra SR. Health system's readiness to provide cardiovascular, diabetes and chronic respiratory disease related services in Nepal: analysis using 2015 health facility survey. <i>BMC Public Health</i> 2020; 20 (1): 1163.	Combined data on primary and secondary healthcare level
37	Gerbert B, Maurer T, Berger T, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. <i>Archives of Dermatology</i> ; 132 (9): 1030-8.	Inadequate or inappropriate results
38	Gordon NP, Hornbrook MC. Older adults' readiness to engage with eHealth patient education and self-care resources: a cross-sectional survey. <i>BMC health services research</i> 2018; 18 (1): 220.	Not relevant to the theme for review
39	Goytia EJ, Rapkin B, Weiss ES, Golub D, Guzman V, O'Connor M. Readiness and capacity of librarians in public libraries to implement a breast cancer outreach and screening campaign in medically underserved communities. <i>Cancer control : journal of the Moffitt Cancer Center</i> 2005; 12 Suppl 2 : 13-20.	Not relevant to the theme for review
40	Gujral UP, Johnson L, Nielsen J, et al. Preparedness cycle to address transitions in diabetes care during the COVID-19 pandemic and future outbreaks. <i>BMJ Open Diabetes Research & Care</i> 2020; 8 (1): 07.	Not relevant to the theme for review
41	Haileamlak A. Preparedness to Respond to the Ever-increasing Cancer Cases. <i>Ethiopian Journal of Health Sciences</i> ; 25 (4): 293-4.	Not relevant to the theme for review
42	Hanusaik N, O'Loughlin JL, Kishchuk N, Paradis G, Cameron R. Organizational capacity for chronic disease prevention: a survey of Canadian public health organizations. <i>European Journal of Public Health</i> ; 20 (2): 195-201.	Combined data on primary and secondary healthcare level
43	Henderson KH, DeWalt DA, Halladay J, et al. Organizational Leadership and Adaptive Reserve in Blood Pressure Control: The Heart Health NOW Study. <i>Annals of Family Medicine</i> ; 16 (Suppl 1): S29-S34.	Inadequate or inappropriate results
44	Heslop L, Power R, Cranwell K. Building workforce capacity for complex care coordination: a function analysis of workflow activity. <i>Human Resources for Health [Electronic Resource]</i> ; 12 : 52.	Not relevant to the theme for review
45	Geboers et al.	Inadequate or inappropriate results
46	Inrig SJ, Higashi RT, Tiro JA, Argenbright KE, Lee SJ. Assessing local capacity to expand rural breast cancer screening and patient navigation: An iterative mixed-method tool. <i>Evaluation and program planning</i> 2017; 61 : 113-24.	Inadequate or inappropriate results
47	Jayanna K, Swaroop N, Kar A, et al. Designing a comprehensive Non-Communicable Diseases (NCD) programme for hypertension	Inadequate or inappropriate results

	and diabetes at primary health care level: evidence and experience from urban Karnataka, South India. <i>BMC Public Health</i> 2019; 19 (1): 409.	
48	Jigjidsuren A, Byambaa T, Altangerel E, et al. Free and universal access to primary healthcare in Mongolia: the service availability and readiness assessment. <i>BMC Health Services Research</i> ; 19 (1): 129.	Inadequate or inappropriate results
49	Jin Y, Zhu W, Yuan B, Meng Q. Impact of health workforce availability on health care seeking behavior of patients with diabetes mellitus in China.	Combined data on primary and secondary healthcare level
50	Joffres C, Heath S, Farquharson J, et al. Defining and operationalizing capacity for heart health promotion in Nova Scotia, Canada. <i>Health Promotion International</i> 2004; 19 (1): 39-49.	Not relevant to the theme for review
51	Jones D, West R, Lester C. Evaluation of changes in primary health care availability and provision from the patient perspective.	Inadequate or inappropriate results
52	Jones R, Ostrem A. Optimising pharmacological maintenance treatment for COPD in primary care. <i>Primary Care Respiratory Journal</i> 2011; 20 (1): 33-45.	Inadequate or inappropriate results
53	Kayser L, Rossen S, Karnoe A, et al. Development of the Multidimensional Readiness and Enablement Index for Health Technology (READHY) Tool to Measure Individuals' Health Technology Readiness: Initial Testing in a Cancer Rehabilitation Setting. <i>Journal of medical Internet research</i> 2019; 21 (2): e10377.	Inadequate or inappropriate results
54	Khunti K, Baker R, Rumsey M, Lakhani M. Approaches to the organization of multi-practice audits in primary health care in the UK. <i>International Journal for Quality in Health Care</i> ; 11 (3): 221-6.	Inadequate or inappropriate results
55	Kaufman ND, Rajataramya B, Tanomsingh S, Ronis DL, Potempa K. Nurse preparedness for the non-communicable disease escalation in Thailand: a cross-sectional survey of nurses. <i>Nursing & Health Sciences</i> 2012; 14 (1): 32-7.	Inadequate or inappropriate results
56	Laatikainen T, Inglin L, Collins D, et al. Implementing Package of Essential Non-communicable Disease Interventions in the Republic of Moldova-a feasibility study. <i>Eur J Public Health</i> 2020.	Inadequate or inappropriate results
57	Landon BE, Hicks LS, O'Malley AJ, et al. Improving the management of chronic disease at community health centers. <i>New England Journal of Medicine</i> 2007; 356 (9): 921-34.	Inadequate or inappropriate results
58	Langer S, Chew-Graham CA, Drinkwater J, et al. A motivational intervention for patients with COPD in primary care: qualitative evaluation of a new practitioner role. <i>BMC Family Practice</i> ; 15 : 164.	Inadequate or inappropriate results
59	Liu J, Yin H, Zheng T, et al. Primary health institutions preference by hypertensive patients: Effect of distance, trust and quality of management in the rural Heilongjiang province of China.	Inadequate or inappropriate results
60	Maarse JA, Ruwaard D, Spreeuwenberg C. The governance of quality management in dutch health care: new developments and strategic challenges. <i>Quality Management in Health Care</i> ; 22 (3): 236-47.	Not relevant to the theme for review
61	Madueno A, Martin A, Peculo JA, Anton E, Paravisini A, Leon A. Usefulness of inspiratory capacity measurement in COPD patients in the primary care setting. <i>International Journal of General Medicine</i> 2009; 2 : 219-25.	Combined data on primary and secondary healthcare level
62	Main DS, Cohen SJ, DiClemente CC. Measuring physician readiness to change cancer screening: Preliminary results. <i>American Journal of Preventive Medicine</i> 1995; 11 (1): 54-8.	Inadequate or inappropriate results
63	Monaghan M, Hilliard M, Sweenie R, Riekert K. Transition readiness in adolescents and emerging adults with diabetes: the role	Inadequate or inappropriate results

	of patient-provider communication. <i>Current Diabetes Reports</i> ; 13 (6): 900-8.	
64	Moynihan M, Saewyc E, Whitehouse S, Paone M, McPherson G. Assessing readiness for transition from paediatric to adult health care: Revision and psychometric evaluation of the Am I ON TRAC for Adult Care questionnaire. <i>Journal of Advanced Nursing</i> ; 71 (6): 1324-35.	Inadequate or inappropriate results
65	Neher M, Landen Ludvigsson M, Enblom A. Preparedness to Implement Physical Activity and Rehabilitation Guidelines in Routine Primary Care Cancer Rehabilitation: Focus Group Interviews Exploring Rehabilitation Professionals' Perceptions. <i>Journal of cancer education : the official journal of the American Association for Cancer Education</i> 2020.	Inadequate or inappropriate results
66	Nilsson GH, Skånér Y, Krakau I, Hassler E, Sundquist K. Primary prevention of first-ever stroke in primary health care: A clinical practice study based on medical register data in sweden.	Inadequate or inappropriate results
67	Nuno-Solinis R. Are Healthcare Organizations Ready for Change? Comment on "Development and Content Validation of a Transcultural Instrument to Assess Organizational Readiness for Knowledge Translation in Healthcare Organizations: The OR4KT". <i>International Journal of Health Policy & Management</i> ; 7 (12): 1158-60.	Inadequate or inappropriate results
68	Nyarko KM, Ameme DK, Ocansey D, Commeh E, Markwei MT, Ohene SA. Capacity assessment of selected health care facilities for the pilot implementation of Package for Essential Non-communicable Diseases (PEN) intervention in Ghana. <i>The Pan African medical journal</i> ; 25 (Suppl 1): 16.	Combined data on primary and secondary healthcare level
69	Ogbimi RI. Leadership in Nigerian health system for cancer prevention and control. <i>African Journal of Medicine & Medical Sciences</i> ; 38 Suppl 2: 49-53.	Inadequate or inappropriate results
70	Ostroff JS, Copeland A, Borderud SP, Li Y, Shelley DR, Henschke CI. Readiness of lung cancer screening sites to deliver smoking cessation treatment: Current practices, organizational priority, and perceived barriers. <i>Nicotine & Tobacco Research</i> 2016; 18 (5): 1067-75.	Not relevant to the theme for review
71	Oyewole EY, Ojewale LY, Abimbola OO. Primary Health Care Nurses' Competencies and Resources Availability for Diabetes Mellitus Care at Local Government Areas of Ibadan. <i>International Journal of Caring Sciences</i> 2020; 13 (1): 368-80.	Not relevant to the theme for review
72	Parchman ML, Anderson ML, Coleman K, et al. Assessing quality improvement capacity in primary care practices. <i>BMC Family Practice</i> ; 20 (1): 103.	Not relevant to the theme for review
73	Pilkerton CS, Singh SS, Bias TK, Frisbee SJ. Healthcare resource availability and cardiovascular health in the USA. <i>BMJ Open</i> 2017; 7 (12): e016758.	Not relevant to the theme for review
74	Radin A, Cote C. Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention and early diagnosis. <i>American Journal of Medicine</i> ; 121 (7 Suppl): S3-12.	Inadequate or inappropriate results
75	Rathish D, Premarathna I, Jayathilake T, et al. Availability of essential medicines in selected public, primary and secondary health care institutions of a rural Sri Lankan district: A spot survey.	Combined data on primary and secondary healthcare level
76	Rogers HE, Akiteng AR, Mutungi G, Ettinger AS, Schwartz JI. Capacity of Ugandan public sector health facilities to prevent and	Combined data on primary and secondary healthcare level

	control non-communicable diseases: an assessment based upon WHO-PEN standards. <i>BMC Health Services Research</i> ; 18 (1): 606.	
77	Roper KL, Thomas AR, Hieronymus L, Brock A, Keck J. Patient and Clinician Perceptions of Prediabetes: A Mixed-Methods Primary Care Study. <i>Diabetes Educ</i> 2019; 45 (3): 302-14.	Inadequate or inappropriate results
78	Schwartz R, Smith C, Speers MA, et al. Capacity building and resource needs of state health agencies to implement community-based cardiovascular disease programs. <i>Journal of Public Health Policy</i> 1993; 14 (4): 480-94.	Inadequate or inappropriate results
79	Shaw RJ, Kaufman MA, Bosworth HB, et al. Organizational factors associated with readiness to implement and translate a primary care based telemedicine behavioral program to improve blood pressure control: the HTN-IMPROVE study. <i>Implementation Science</i> ; 8 : 106.	Inadequate or inappropriate results
80	Sorensen A, Le LW, Swami N, et al. Readiness for delivering early palliative care: A survey of primary care and specialised physicians. <i>Palliative Medicine</i> 2020; 34 (1): 114-25.	Combined data on primary and secondary healthcare level
81	Soylu TG, Cuellar AE, Goldberg DG, Kuzel AJ. Readiness and Implementation of Quality Improvement Strategies Among Small- and Medium-Sized Primary Care Practices: an Observational Study. <i>Journal of General Internal Medicine</i> 2020.	Not relevant to the theme for review
82	Tanjasiri SP, Tran JH. Community capacity for cancer control collaboration: weaving an Islander Network for Cancer Awareness, Research and Training for Pacific Islanders in Southern California. <i>Cancer Detection & Prevention</i> ; 32 Suppl 1 : S37-40.	Inadequate or inappropriate results
83	Tompkins JW, Mequanint S, Barre DE, et al. National Survey of Indigenous primary healthcare capacity and delivery models in Canada: the TransFORMATION of IndiGENous PrimAry HEAlthcare delivery (FORGE AHEAD) community profile survey. <i>BMC Health Services Research</i> ; 18 (1): 828.	Combined data on primary and secondary healthcare level
84	Weeks DL, Polello JM, Hansen DT, Keeney BJ, Conrad DA. Measuring primary care organizational capacity for diabetes care coordination: the Diabetes Care Coordination Readiness Assessment. <i>Journal of General Internal Medicine</i> ; 29 (1): 98-103.	Not relevant to the theme for review